What's Happening?
Abbott CEO Robert Ford announced that the company is on track to launch its pulsed field ablation (PFA) system in the U.S. next year, following competitors like Medtronic, Boston Scientific, and Johnson
& Johnson. Abbott's Volt PFA system, which received Europe's CE mark in March, is expected to gain FDA approval in 2026. The system is designed to deliver deeper, more durable lesions with real-time contact visualization, potentially reducing the number of applications and allowing procedures under conscious sedation. Abbott's electrophysiology business, including PFA devices, reported $705 million in sales in the third quarter, a 15% increase year over year. Additionally, Abbott plans to launch a dual-analyte sensor in its diabetes business, which could help prevent diabetic ketoacidosis.
Why It's Important?
Abbott's entry into the PFA market is significant as cardiac ablation is increasingly preferred for treating heart rhythm disorders due to its safety and efficiency. The launch of the Volt PFA system could enhance Abbott's position in the electrophysiology market, driving growth and innovation. The dual-analyte sensor in the diabetes business represents a potential breakthrough in diabetes management, offering improved monitoring and prevention of complications. These developments could lead to expanded coverage and adoption of Abbott's medical devices, benefiting patients and healthcare providers.
What's Next?
Abbott is preparing for the launch of its Volt PFA system in the U.S., with FDA approval anticipated in 2026. The company may focus on marketing and distribution strategies to ensure successful adoption of the system. In the diabetes sector, Abbott is working towards expanding Medicare coverage for its continuous glucose monitors, potentially increasing access for patients with Type 2 diabetes. The company is also anticipating proposed coverage for non-insulin-dependent patients, which could further boost sales and market penetration.
